PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OIPE

U6 0 1 2003	TRANSMITTAL
PANEN!	FORM

(to be used for all correspondence after initial filing)

Application Number	10/088,160	١
Filing Date	March 13, 2002	h.
First Named Inventor	Alexander KOZAK	15/1.
Group Art Unit	1624 CA	
Examiner Name	John M. Ford	1 2003
Attorney Docket Number	800.1015	160000
SURES (check all that apply)] ~~00
ment Papers	After Allowance Communication to	

Total Number of Pages in This Submission			6	Attorney	y Docket Number	800.1015			
			ENCLO	SURES (d	check all that apply)				
Fee Tr	ransmittal	Form	Assignment Papers (for an Application)			After Allowance Communication to Group			
Fee Attached			Drawing(s)				Appeal Communication to Board of Appeals and Interferences		
Amend	dment / Re	esponse	Licensing-related Papers				ommunication to Group lice, Brief, Reply Brief)	;	
Aft	ter Final		Petition			Proprietary	y Information		
Aff	Affidavits/declaration(s)			Petition to Convert to a Provisional Application			Status Letter		
Extension of Time Request			Power of Attorney, Revocation Change of Correspondence Address			Other Enclosure(s) (please identify below):			
Express Abandonment Request			Terminal Disclaimer Request for Refund CD, Number of CD(s)						
		losure Statement	CD, NI	umber of Ci	D(s)	<u></u>	··· W		
Certified Copy of Priority Document(s)			Remarks						
Response to Missing Parts/									
Incomp	plete Appli	cation							
		Missing Parts R 1.52 or 1.53							
u		1.52 07 1.50							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT									
Name		n, Davidson & Kappel							
Address	485 Sev	renth Avenue, 14 th Flo	or			·- -			
City New York			State	NY	Zip Code	10018			
Country	try USA Tele		Telepho	hone (212) 736-1940		Fax	(212) 736-2427		
Individua	al name	Morey B. Wildes Re	g. No. 36,9	68					
Signature Trunch Zungl									
Date		July 30, 2003		7					
_		CI	ERTIFICA"	TE OF TR	ANSMISSION/MAII	ING		=	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Typed or printed name	Patricia Kane	".	
Signature	Hatriciakane	Date	July 30, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AUG 0 1 2003 PRANCE RE:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

KOZAK, et al.

Serial No.:

10/088,160

Filing Date:

September 13, 2000

For:

PHOSPHOLIPID PRODRUGS OF ANTI-

PROLIFERATIVE DRUGS

Examiner:

John M. Ford

Art Unit:

1624

Mail Stop: NON-FEE AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

July 30, 2003

RESPONSE TO OFFICE ACTION

SIR:

In response to the Office Action dated June 30, 2003 from the U.S. Patent and Trademark Office regarding the above-identified application, Applicants hereby respond as follows:

REMARKS

In the Office Action dated June 30, 2003, the Examiner stated that all of pending claims 1-16 and 18-30 are subject to a Restriction Requirement, contending that claim 1 contains multiple different compounds that are patentably distinct, such that there is a lack of unity of invention in the application. According to the Examiner, 37 CFR §1.475 allows examination of one compound invention, one process for making that compound and one process for using that compound. Thus, the Examiner has divided the claims into the following five groups that he contends are separate inventions and requires that a single invention be elected:

(I) Claims 1-11 drawn to various prodrugs classified various dependent on what the anti-proliferative drug is. If this group is elected, a further election of a specific drug is required, e.g. methotrexate, flurorouridine, etc.